X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs STRIDES PHARMA SCIENCE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA STRIDES PHARMA SCIENCE SANOFI INDIA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 37.2 51.2 72.7% View Chart
P/BV x 7.0 1.1 629.6% View Chart
Dividend Yield % 0.5 0.4 124.1%  

Financials

 SANOFI INDIA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
STRIDES PHARMA SCIENCE
Mar-18
SANOFI INDIA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs4,9451,147 431.1%   
Low Rs3,901642 607.6%   
Sales per share (Unadj.) Rs1,081.8317.2 341.0%  
Earnings per share (Unadj.) Rs141.67.8 1,804.5%  
Cash flow per share (Unadj.) Rs185.925.1 742.1%  
Dividends per share (Unadj.) Rs33.002.00 1,650.0%  
Dividend yield (eoy) %0.70.2 333.7%  
Book value per share (Unadj.) Rs868.8274.3 316.8%  
Shares outstanding (eoy) m23.0389.50 25.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.8 145.0%   
Avg P/E ratio x31.2114.0 27.4%  
P/CF ratio (eoy) x23.835.7 66.6%  
Price / Book Value ratio x5.13.3 156.1%  
Dividend payout %23.325.5 91.4%   
Avg Mkt Cap Rs m101,86280,058 127.2%   
No. of employees `0003.22.5 129.2%   
Total wages/salary Rs m3,6854,341 84.9%   
Avg. sales/employee Rs Th7,691.911,325.8 67.9%   
Avg. wages/employee Rs Th1,137.71,731.4 65.7%   
Avg. net profit/employee Rs Th1,006.5280.1 359.4%   
INCOME DATA
Net Sales Rs m24,91428,394 87.7%  
Other income Rs m807941 85.8%   
Total revenues Rs m25,72129,334 87.7%   
Gross profit Rs m5,3723,965 135.5%  
Depreciation Rs m1,0221,540 66.3%   
Interest Rs m111,962 0.6%   
Profit before tax Rs m5,1461,403 366.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,88697 1,938.3%   
Profit after tax Rs m3,260702 464.3%  
Gross profit margin %21.614.0 154.4%  
Effective tax rate %36.66.9 528.5%   
Net profit margin %13.12.5 529.2%  
BALANCE SHEET DATA
Current assets Rs m14,43224,836 58.1%   
Current liabilities Rs m6,01018,993 31.6%   
Net working cap to sales %33.820.6 164.3%  
Current ratio x2.41.3 183.6%  
Inventory Days Days6171 85.8%  
Debtors Days Days28113 25.1%  
Net fixed assets Rs m7,99134,289 23.3%   
Share capital Rs m230895 25.7%   
"Free" reserves Rs m19,77823,651 83.6%   
Net worth Rs m20,00824,546 81.5%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m27,77065,437 42.4%  
Interest coverage x468.81.7 27,335.7%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.4 206.8%   
Return on assets %11.84.1 289.3%  
Return on equity %16.32.9 569.6%  
Return on capital %25.86.9 373.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,30615,697 40.2%   
Fx outflow Rs m5,257735 714.8%   
Net fx Rs m1,04914,962 7.0%   
CASH FLOW
From Operations Rs m4,3511,871 232.6%  
From Investments Rs m-7875,826 -13.5%  
From Financial Activity Rs m-1,884-10,157 18.5%  
Net Cashflow Rs m1,680-2,615 -64.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 37.8 38.1%  
FIIs % 14.6 8.6 169.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.9 40.5%  
Shareholders   15,184 56,241 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 20, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - WYETH LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS